ATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3. It inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a... This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy.
- Mechanism
- Curator reviewed
ATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3. It inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a critical role in tumor angiogenesis. Beta integrins, including beta(1), beta(3) and beta(5) subtypes, are present on endothelial cells and mediate endothelial cell-extracellular matrix interactions. Of particular interest to cancer progression is integrin alpha(5)beta(1) which is expressed on activated endothelial cells and plays a critical role in tumor angiogenesis. Likewise alpha(5)beta(1) integrin is also present on many tumor cells where is plays a key role in adhesion and migration and hence blocking this integrin can affect tumor progression both directly and also indirectly through the prevention of angiogenesis.
- Primary indication
- Investigated for use/treatment in brain cancer and cancer/tumors (unspecified).Curator reviewed
- Formula / weight
- C23H35N9O8S · 597.65 g/mol (avg)
- Code names
- ATN-161 · ATN-161 free base
Resolves to
MMHDBUJXLOFTLC-WOYTXXSLSA-NSMILESCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=OWhat you can answer from here — as of July 03, 2026
Which companies are running trials of ATN-161, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account